All In Biotech

Drug Trial Radar · NCT02485717

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy and Pharmacokinetics of Natroba™ (Spinosad) for the Treatment of Scabies

Last checked: Nov 20, 2026Latest source record: May 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 291 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

291

Actual

Start

May 2, 2017

Primary completion

Jun 25, 2018

Study completion Jun 25, 2018

Sponsor

Lead sponsor
ParaPRO LLCIndustry
Sponsor type
Industry
Collaborators
Concentrics Research
First posted
Jun 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and efficacy of Natroba (spinosad) topical suspension versus placebo for the clinical cure of scabies after a single treatment. The trial will also assess the pharmacokinetics (PK) of spinosad and benzyl alcohol following a single dose of Natroba™ in pediatric subjects 4-16 years of age. These subjects will be a separate population of pediatric subjects.

Conditions

  • Scabies

Interventions

  • spinosad topical suspension, 0.9%Drug

    Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

  • PlaceboOther

    Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Index Subjects Completely Cured of Scabies After a Single TreatmentTime frame: 28 days after treatment

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Elk Grove Clinical Research

    Elk Grove, California

  • The Chappel Group Research

    Kissimmee, Florida

  • San Marcus Research

    Miami, Florida

  • L&C Professional Medical Research Institute

    Miami, Florida

  • LSRN Research

    West Palm Beach, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.